A Phase II Study of Mosunetuzumab as Initial Chemotherapy-Free Treatment for Follicular Lymphoma

Share

Full Title

An Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy

Purpose

The purpose of this study is to assess the safety and effectiveness of the drug mosunetuzumab for people with follicular lymphoma who have not yet received treatment. Mosunetuzumab binds to a cancer cell and a T cell (which plays a key role in the immune system) at the same time. Researchers think that mosunetuzumab may strengthen the immune system’s ability to fight cancer cells by activating a patient’s own cells to destroy the tumor. Mosunetuzumab is given as a subcutaneous (under the skin) injection.

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have follicular lymphoma that has not yet been treated with anticancer medication.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

 

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Lorenzo Falchi 646-608-3705.

Protocol

22-100

Phase

II

Disease Status

Newly Diagnosed

Investigator

Co-Investigators